Daily symptom tracking exposes sharp heterogeneity in pernicious anaemia treatment response
Pernicious anaemia is usually managed with fixed-interval vitamin B12 replacement, yet daily lived experience often tells a less orderly story. Symptoms can linger, recur before the next injection, or improve only in fragments across fatigue, pain, cognition, and sensory complaints. This longitudinal study used high-frequency digital symptom monitoring to capture that variability in real time, rather than relying on retrospective recall or infrequent clinic visits.
Sixty-eight UK adults with pernicious anaemia contributed more than 5,100 person-days of symptom data over a mean follow-up of 76 days. The design matters because symptom fluctuation is not a minor detail in this disease; it is the clinical signal. Fixed-interval replacement may restore serum B12 biology, yet it does not guarantee uniform symptom relief across patients or across symptom domains.
Most symptom burden stayed anchored to the individual, not the day
The clearest pattern was stability within person. Across symptom domains, most variance reflected between-person differences, with intraclass correlation coefficients ranging from 0.58 to 0.80. In practical terms, one participant’s daily symptom profile tended to remain recognizably different from another’s, even as treatment cycles advanced. This supports the idea of persistent symptom phenotypes in pernicious anaemia rather than a single uniform recovery pattern.
A 71% responder rate for composite symptom burden suggests that many patients do experience meaningful benefit from injections. Composite scores fell from a median of 4.65 to 2.36 in responders, a change that reached statistical significance. The remaining 29% are harder to dismiss. Their composite burden stayed essentially unchanged, from 3.59 to 3.58, indicating that some patients continue to report substantial symptoms despite standard replacement.
Cognitive symptoms improved first, while other domains lagged behind
The timing of recovery varied by symptom type, and the sequence is clinically revealing. Cognitive symptoms improved earliest, typically within 24 to 72 hours after an injection. Fatigue and pain followed with peak responses at 3 to 5 days, while neuro-sensory symptoms reached maximal improvement at 4 to 6 days. These staggered trajectories fit with the biology of deficient cobalamin states, where neuronal and metabolic recovery does not unfold on a single clock.
Cognition’s earlier rebound may reflect rapid correction of metabolic stress in vulnerable neural pathways, whereas pain and fatigue may depend on slower downstream shifts in energy handling, peripheral nerve function, or central symptom perception. Neuro-sensory symptoms appearing later still point to a distinct recovery tempo in systems already stressed by prolonged deficiency. The body does not repair every symptom through the same mechanism, and the data make that plain.
Responses also clustered within individuals. People who improved in one symptom domain often showed improvement in others, but the pattern of response was not identical across all participants. That clustering implies responder phenotypes, with some patients showing broad multisystem benefit and others showing little measurable change despite repeated treatment.
Injection frequency may mark a subgroup with heavier symptom burden
Treatment interval appeared linked to both baseline burden and apparent response. Overall symptom burden improved most among participants receiving monthly injections, while those injecting weekly or more often had higher pre-injection burden and smaller improvements. That pattern should not be read as proof that more frequent injections cause worse outcomes. A more cautious interpretation is that patients with more severe or more labile symptoms may already have been selected into shorter dosing intervals, bringing greater symptom instability into the treatment window.
Still, the finding raises a bedside question: if patients on more frequent injections continue to report heavier symptom burden before treatment, standard fixed schedules may not be matching individual symptom recurrence. The underlying autoimmune failure in pernicious anaemia produces chronic dependence on exogenous B12, but the pace at which symptoms recur may differ substantially from one patient to the next. A rigid interval can miss that reality.
What high-frequency tracking adds to care
Daily symptom capture offers a way to see treatment response with much finer resolution than routine follow-up permits. Instead of a single recall of “better” or “not better,” the monitoring approach separates cognitive, fatigue, pain, and neuro-sensory trajectories and shows when each one changes. That granularity could help identify patients whose symptoms recur early, whose response is partial, or whose burden remains high despite apparently adequate replacement.
The method also exposes a challenge in pernicious anaemia management: symptom severity and biochemical correction are related but not interchangeable. Patients may improve at different speeds, in different domains, and to different degrees. Fixed-interval vitamin B12 replacement may remain the default, but these data argue for a more individualized, symptom-guided approach as a research question and a care model.
The study has the limitations expected of an observational preprint. Symptom reporting was self-reported, treatment patterns were not randomized, and the cohort came from recruitment through the Pernicious Anaemia Society, which may enrich for patients with ongoing symptom concerns. Even so, the volume of daily data and the consistency of the response patterns make one point difficult to ignore: in pernicious anaemia, treatment response is not a single curve but several overlapping ones, and some patients do not fit the schedule they are given.